About this Journal Submit a Manuscript Table of Contents
Journal of Skin Cancer
Volume 2012 (2012), Article ID 286480, 6 pages
Clinical Study

Treatment of Basal Cell Carcinomas with Pulsed Dye Laser: A Case Series

1Minars Dermatology Skin and Laser Center, 4060C Sheridan Street, Hollywood, FL 33021, USA
2Department of Dermatology and Cutaneous Surgery, Voluntary Faculty, University of Miami Hospital, 1295 NW, 14th Street, South Building, Suites K-M, Miami, FL 33136, USA

Received 24 August 2012; Revised 22 November 2012; Accepted 26 November 2012

Academic Editor: Giuseppe Argenziano

Copyright © 2012 Norman Minars and Marianna Blyumin-Karasik. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. Basal cell carcinoma (BCC) is the most prevalent skin cancer. Because of its highly vascular characteristic, it is amendable to treatment with pulse dye laser (PDL). The goal of this study is to determine the safety and efficacy of PDL therapy for mostly facial BCCs. Materials and Methods. Sixteen men and thirteen women (29 total) with 39 biopsy-proven BCCs were treated with 1–4 PDL (595 nm) therapies at 2–4-week intervals. The treatment parameters included pulse energy of 15 J/cm 2, pulse length of 3 millisecond, with no dynamic cooling, and 7 mm spot size. The age of the patients was 30–90 years (mean 73 years). Response rates were evaluated by the clinical assessments with mean followup of 11 months. Results. Twenty-four patients with thirty-two tumors reached at least three months followup: 24/32 (75%) tumors with complete resolution (mean 3 treatment sessions); 5/32 (16%) tumors recurred; 3/32 (9%) tumors with incomplete responses after four treatments. Minimal side effects and discomfort were experienced by the patients with PDL therapy. Conclusion. PDL is a safe, tolerable, and moderately effective method of treating various BCCs. The ideal niche and standardized settings for PDL treatment of BCCs are yet to be determined.